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A comprehensive search of PubMed and Embase was performed in January 2015 to examine the available
literature on validated diagnostic models of the pre-test probability of stable coronary artery disease and to
describe the characteristics of the models. Studies that were designed to develop and validate diagnostic
models of pre-test probability for stable coronary artery disease were included. Data regarding baseline patient
characteristics, procedural characteristics, modeling methods, metrics of model performance, risk of bias, and
clinical usefulness were extracted. Ten studies involving the development of 12 models and two studies focusing
on external validation were identified. Seven models were validated internally, and seven models were
validated externally. Discrimination varied between studies that were validated internally (C statistic 0.66-0.81)
and externally (0.49-0.87). Only one study presented reclassification indices. The majority of better performing
models included sex, age, symptoms, diabetes, smoking, and hyperlipidemia as variables. Only two diagnostic
models evaluated the effects on clinical decision making processes or patient outcomes. Most diagnostic models
of the pre-test probability of stable coronary artery disease have had modest success, and very few present data
regarding the effects of these models on clinical decision making processes or patient outcomes.
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’ INTRODUCTION
Coronary artery disease (CAD) is a common public health
problem that is frequently associated with high mortality and
increased health costs. Invasive coronary arteriography (ICA),
the gold standard procedure for diagnosing CAD, has been
widely used in clinical practice. Although this procedure can
reduce the misdiagnosis of CAD in patients, it may also be an
excessive medical treatment. In a recent report, only 41% of
patients who underwent ICA were then diagnosed with
obstructive CAD, suggesting that at least half of the people
who undergo this expensive procedure do not need it (1).
Models that can predict the pre-test probability (PTP) of stable
CAD in patients may serve as an effective ‘‘gatekeeper’’ to
identify those who are at a high risk and who may benefit
from further diagnostic investigation.
The European and American guidelines have recently pla-
ced great importance on the initial risk stratification of sus-
pected CAD to avoid unwarranted examinations and have
recommended the Duke clinical score (DCS) and Diamond-
Forrest model (DFM) as the preferred models to calculate
the PTP (2,3). However, some studies have suggested that
these two risk assessment methods perform poorly in Asian
populations, especially in China (4,5). Indeed, differences in
derivation, inconsistent external validation, and complexity of
the models often exist, which limit their general application in
daily clinical practice. In addition, the effects of adopting
clinical prediction rules to guide decision making and improve
patient outcomes are often not evaluated. Therefore, we
performed a systematic review of the available literature on
validated diagnostic models of PTP for obstructive CAD and
described the performance of the models and their clinical
utility to better understand the development of diagnostic
models and to help clinicians select the ideal model to use in
their practices.
’ METHODS
Literature search
We conducted a systematic review of the available literature
using the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines (6). PubMed and
Embase were searched in January 2016 by professional
document retrieval personnel from the Xiang-Ya Medical
Library of Central South University using the following search
terms: ’coronary heart disease,’ ’coronary artery disease,’DOI: 10.6061/clinics/2017(03)10
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’stable angina,’ ’pre-test probability,’ and ’probabilistic model.’
Reference lists in relevant meta-analyses and reviews were
manually examined. No language or data restrictions were
included. All of the potentially relevant studies were examined
in their entirety.
Selection criteria
Clinical prediction models can often be divided into
diagnostic models that estimate the probability of a specific
diagnosis and prognostic models that estimate the prob-
ability of expected outcomes over a given period of time (7).
In patients with suspected CAD, diagnostic models can
provide a method to calculate the PTP, whereas prognostic
models, such as the Framingham risk score, PROCAM
(Prospective Cardiovascular Munster) score, and SCORE
(Systematic Coronary Risk Evaluation) score, are used to
stratify risk and to predict the clinical outcomes but not the
anatomical results. In addition, prognostic models are often
developed using asymptomatic patients (8,9). In our review,
we mainly focused on diagnostic models.
We included articles if they evaluated the characteristics
of a diagnostic model of CAD, regardless of whether they
included information about the development or validation of
the models. The inclusion criteria were as follows: (1) the
model contained at least two independent variables; (2) the
eligible clinical endpoint was a stable CAD; and (3) because
predictive factors that are derived in a single population
could lack validity and applicability, we included only stu-
dies that presented both the development and validation
of the diagnostic model. We did not specify the method of
validation in advance, nor did we exclude studies where the
derivation and validation cohorts (possibly from other stu-
dies) were drawn from the same population. The exclusion
criteria were: (1) the model was developed using patients
with acute coronary syndrome, unstable chest pain, a history
of myocardial infarction, or previous revascularization (per-
cutaneous coronary intervention or coronary artery bypass
graft surgery); (2) the clinical endpoint was myocardial
infarction or death; or (3) the article was an unpublished
conference abstract.
Data extraction
Two reviewers (Ting H and Xing L) extracted data from
the included studies. The following items were recorded in
standardized forms: the names of the authors, publication
year, definition used for CAD, sample size, and method used
for model development. We also noted the variables included
in the model and the geographic origin of each study. If an
article described more than two models, we considered all of
the possible models as eligible for inclusion in our review. We
also extracted metrics of model performance (discrimination,
calibration, and reclassification).
Correspondence with the authors of the included studies
was initiated as necessary. If discrepancies occurred, a con-
sensus was reached by all authors through discussion. All of
the obtained data were carefully examined for accuracy.
Model performance and validation
We evaluated the internal validity of each model by
examining its discrimination power, calibration, and reclas-
sification. The traditional metric used to assess model
discrimination, the C statistic (equivalent to the area under
the receiver operating characteristic curve), was extracted.
This value represented the model’s ability to distinguish
patients with and without CAD. Typically, modest discrimi-
native ability was defined by C statistic values that ranged
from 0.7 to 0.8, whereas values that were greater than 0.8
were indicative of good discriminative ability. Other metrics,
such as sensitivity and specificity, were included if the C
statistic was not reported.
To determine the calibration, we used the Hosmer-
Lemeshow statistic, which was used to verify that the degree
of the average prediction was consistent with the observed
outcome. A larger p-value indicated better calibration abi-
lity (a p-value40.1 was considered evidence of adequate
calibration). If the Hosmer-Lemeshow statistic was not
reported, we extracted information on the calibration plot,
if shown.
Reclassification was evaluated using the net reclassi-
fication improvement (NRI). The NRI compares the fre-
quency with which appropriate reclassification occurs to the
frequency with which inappropriate reclassification occurs
in the use of the new model (10). For this test, a value of
*po0.05 suggested that a significantly greater number of
patients were being reclassified appropriately than were
being reclassified inappropriately.
We also evaluated the generalizability of each diagnostic
model by determining whether it had been externally vali-
dated in an independent patient population, either in the
original study or in a subsequent publication.
Quality assessment and clinical usefulness
The methodological quality and risk of bias of each model
were evaluated by two reviewers in accordance with the
criteria recommended by Hayden and colleagues (11,12). The
criteria were as follows: study participation, study attrition,
prognostic factor selection, prognostic factor measurement,
outcome measurement, statistical analysis, and reporting of
model performance (discrimination, calibration, and reclas-
sification). All of the items were assigned a value of ’low
risk,’ ’high risk,’ or ’uncertain.’
We also assessed the clinical usefulness of each model,
which was defined as the combination of clinical utility and
usability. For clinical utility (the effect on a clinical decision
that is linked to a risk category or threshold), we determined
whether the authors linked their models to specific risk
categories and discussed how the risk categories would aid
diagnostic evaluations. For usability (the availability of a
clinical decision tool), we noted whether the authors inclu-
ded a calculator or risk score that would facilitate knowledge
translation and use at the bedside.
’ RESULTS
Included studies
A total of 1333 studies were identified through PubMed
and Embase searches. After removing duplicate studies,
1175 abstracts were screened. A total of 26 relevant full-text
articles were assessed for eligibility, of which 12 trials com-
prising 12 unique risk diagnostic models fulfilled the inclu-
sion criteria.
Fourteen trials of predictive models for suspected CAD
did not fulfill our inclusion criteria and were excluded
because they consisted of unpublished abstracts (n=6), the
populations did not meet our criteria (n=2), the model was
not multivariate (n=1), or the risk scores were not validated
(n=5) (Figure 1).
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Study characteristics and pertinent models
Ten studies (13-22) reporting the development of 12 models
to predict CAD and two studies (4,23) focusing on external
validation of models were included in the systematic review.
A total of 53,108 patients (range 186 to 24,251 patients) were
involved (not including Diamond 1979, which described an
analysis using Bayes Theorem and did not specify the number
of patients) (Table 1). The data sources for five of the models
were multicenter trials. Only two of the models were develo-
ped using Asian populations, whereas the remainder were
developed using Western populations. The outcomes of
interest differed between models and represented substantial
heterogeneity. These outcomes of interest included severe
CAD in two models, functionally significant CAD in another
model, and obstructive CAD in the remaining models. In
terms of defining obstructive CAD, five models defined it as
having at least one vessel with at least 50% diameter stenosis,
while the remaining model defined it as having at least one
vessel with X75% stenosis. The reference standards for dia-
gnosing CAD included two procedures, ICA and coronary
computed tomography angiography (CTA). Regarding model
development methods, only one study used Bayesian-based
algorithms, while the others used multivariable logistic regres-
sion analyses.
The number of predictors in each model ranged from three
to 10 (Table 2). Nearly all of the diagnostic models included
age, sex, and chest pain symptom as variables. Other
common measures included in the majority of the risk
models were diabetes mellitus, hypertension, smoking, and
hyperlipidemia. Very few of the models included the hospital
setting as a variable. Only one model included estrogen
status or genetic profile as a risk factor.
Model performance and validation
Seven models were validated internally, one with the
bootstrap method, two with split samples (14,19), and four
by cross-validation using the same population (18,20). Nine
models reported the C statistic for the validation cohorts,
which ranged from 0.49 to 0.88, indicating a degree of
discriminative performance that varied from poor to
excellent. Seven models were validated externally. Among
those, four models (13-15,17) were reported in more than one
external validation study, and their discriminating power
showed a weakening trend in recent years (from 0.87 to 0.63).
Only two studies reported calibration using the Hosmer-
Lemeshow test for the derivation cohort, and both were
adequate (18,21).The NRI was reported in one study (20)
(Table 3).
Of the 12 models, only two had good discriminating
power upon validation (C statistic 40.80). Eight and nine
predictors were present in these two models. These two
higher-performing models included the following risk
factors: sex, age, symptoms (chest pain), diabetes status,
smoking status, and hyperlipidemia status. In addition to the
previously listed common risk factors, one model also
included the coronary calcium score, hypertension status,
and hospital setting, whereas the other included the ECG
results and history of previous myocardial infarctions.
Figure 1 - Flow chart for eligible studies.
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Six models had moderate discriminative ability (C statistics
of 0.70-0.80). These models included the following risk
factors: chest pain symptoms (five models), diabetes or
hyperlipidemia status (four models), hypertension or smok-
ing status (three models), and hospital setting (two models).
Other risk factors, such as history of cerebral infarction or
peripheral vascular disease, were included only in one
model. All models included sex and age as risk factors.
Quality assessment and clinical usefulness
Important differences were present in the bias risk among
the studies, with no single study satisfying all seven var-
iables (Table 4). Although all studies adequately described
subject selection and the certainty of the study outcomes,
study attrition was described only in one of the studies. In
addition, most of the studies on the 12 models provided little
information on the selection (nine models) and measurement
(seven models) of the prognostic factors.
As described above, information on model calibration and
reclassification was absent from most studies. In addition,
only two studies excluded patients with missing data, and
the remaining studies did not report the amount of missing
data. None of the studies reported the use of imputation
techniques.
Half of the models (six of 12) stratified their cohorts
into risk categories (low, moderate, and high risk). However,
only one model explained how risk category assignment
would affect diagnostic or therapeutic decisions. Simple risk
calculators or web-based calculators were provided in three
of the studies. One study evaluated the implications of the
diagnostic model on clinical decision making and patient
outcomes.
’ DISCUSSION
In our systematic review, we identified 10 studies that
described 12 diagnostic models for estimating the probability
of CAD, and we found that these models yielded similar
discriminative abilities. Only two of the models were assessed
in clinical practice. Our study is the first to synthesize the
available literature on predictive models of the PTP calculation
for CAD, and it highlights the need for further development
and refinement of these models.
Model performance and validation
Only two of the models exhibited good discrimination
based on the C statistic. However, one model included the
coronary calcium score, which was assessed by CTA, as a
risk factor. Because decisions on diagnostic testing are
usually made before CTA is performed, inclusion of the
coronary calcium score as a variable in the model limits its
usefulness. The C statistic from the external validation of one
of the other models showed a weakening trend (0.87 to 0.63)
in recent years. An important cause of this trend is that the
guidelines recommend using predictive models for PTP prior
to non-invasive testing; therefore, this study chose CTA as
the reference standard, whereas previous studies often
regarded ICA as the reference standard. The model was
developed using a population with a high prevalence of
CAD who underwent ICA but was validated in a population
with a low prevalence of CAD who underwent CTA. This
caused the model to show poor discriminative ability.
Indeed, an analysis restricted to patients who underwent
ICA could be affected by verification bias. Other reasons forTa
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this phenomenon included that the entire population used to
develop this model lived in the USA, and the model was
developed 30 years ago. The differences in prevalence of risk
factors and the homogeneity in some of the study popula-
tions limit the generalizability of these models. Therefore, a
PTP assessment model should be carefully chosen based on
the clinical characteristics of the population of interest.
Almost all of the models were developed using multivariable
logistic regression analysis, but the performance of these
models was unsatisfactory. Several studies have demonstrated
that data mining is a novel and promising approach for
enhancing the performance ability of a model. Green et al. (24)
compared the abilities of artificial neural networks (ANN) and
multiple logistic regression models to predict acute coronary
syndrome in the emergency room. The results of this compa-
rison showed that the C statistics of the best ANN ensemble
and the best logistic regression model were 0.81 and 0.76,
respectively (*p=0.03) (24). Similarly, Alizadehsani et al. (25)
used data mining for the diagnosis of CAD and showed that
characteristic chest pain, region RWMA2, and age were the
most effective features, in addition to the features created using
Information Gain. In addition, using this method and the
feature creation algorithm, 94.08% accuracy was achieved,
which is higher than current approaches in the literature (25).
Future studies could use data mining to develop PTP calcu-
lation models for CAD.
Chest pain characteristics were incorporated into nearly all
of the models as a risk factor. However, some studies show
that chest pain categorization has a limited ability to predict
substantial CAD. When patient symptoms are used to pre-
dict substantial CAD, dissociation frequently occurs between
coronary atherosclerosis and ischemic heart disease. Angina
can occur in the absence of obstructive lesions and in two of
three patients with stable angina (26). Furthermore, women
who undergo ICA due to chest pain are more likely to
present with less extensive CAD than men. Women are also
more likely to show evidence of myocardial ischemia and
non-obstructive CAD (27). Therefore, using only symptoms
as the main variables in the model may overestimate the
probability of CAD, especially in women. Some variables
specific to women should be considered during model devel-
opment. Previous studies have demonstrated that adding
gestational diabetes mellitus(GDM) and estrogen status to
the Updated Diamond-Forrest model (UDFM) can result in a
significant NRI (*p=0.04) (28). Our review included a model
that incorporated estrogen status as a risk factor. Unfortu-
nately, we found that this model performed poorly in the
Middle Eastern cohort but was still better than the DFM,
especially in symptomatic women (4,29).
Use of diagnostic models in clinical practice
Although predictive models for the PTP of CAD have been
a focus of research for approximately 10 years, acceptance by
clinicians has been low. However, the ability to exclude
clinically significant CAD using the PTP in even a small
percentage of patients with normal coronary arteries could
be very beneficial. According to a recent study, the rigid
application of the NICE chest pain guidance, which is
recommended for use in the DFM and DCS models for the
PTP calculation, may result in up to two of three patients being
excluded from further cardiac examinations (30). Several
important factors may limit the application of these models
Table 2 - Variables included in the predictive models of pre-test probability of coronary heart disease.
Study (sample size)
Variable Yang
et al.
(22)
Fujimoto
et al.
(21)
Caselli
et al.
(20)
Chen
et al.
(19)
Genders
et al. (1)
(18)
Genders
et al. (2)
(18)
Genders
et al. (3)
(18)
Genders
et al.
(17)
Rosenberg
et al.
(16)
Morise
et al.
(15)
Pryor
et al.
(14)
Diamond
and
Forrester
(13)
Demographic
Age O O O O O O O O O O O
Sex O O O O O O O O O O O
Medical history
Diabetes mellitus O O O O O O O
Hypertension O O O O O
Previous MI O
Hyperlipidemia O O O O O O O
Cerebral infarction O
Peripheral vascular disease O
Clinical presentation/
physical examination
Chest pain O O O O O O O O O O
Coronary calcium score O
AVC O
Abnormal ECG O O
Personal history
Obesity O
Smoking O O O O O O
Family history of CAD O O
Laboratory values
AST O
hs-CRP O
LDL O
HDL O O
Estrogen status O
Others
Hospital setting O O O
Genes O
Abbreviations:MI, myocardial infarction; AVC, aortic valve calcification; AST, aspartate aminotransferase; hs-CRP, high-sensitivity C-reactive protein; LDL,
low-density lipoprotein; HDL, high-density lipoprotein
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in clinical practice. First, the risk factors included in the models
are not readily available to physicians. For example, the DCS
relies on the interpretation of an ECG and blood tests, whereas
the DFM is more straightforward because it includes only
information on age, sex, and symptoms. Therefore, compared
to the DFM, it can be argued that the added variables in the
DCS are not worth while because a more parsimonious risk
assessment tool is most likely to be used in mainstream clinical
practice (31). Second, unlike the Framingham risk score, almost
all of the models in this review do not have an online calculator,
which would make it difficult for doctors to calculate the PTP
because they would need to use a complex formula. To enhance
clinical utilization, the models should be based on demographic
information and past histories that are typically accessible
in real-world clinical practice. Equally important is the avai-
lability of electronic or web-based calculators to facilitate use at
the bedside.
In addition, limited data are available regarding the use
of these models in clinical practice and their effect on
clinical decision making and cost-effectiveness. Only the
DFM and DCS models were studied in a letter to the Editor.
The report on these models showed that by following the
standard diagnostic pathway, the total cost of examining
all patients was d102,731, compared to d198,495 for the
diagnostic pathway proposed by the NICE chest pain gui-
dance (32).
Clinical Implications
In general, our review could help clinicians better under-
stand the development of diagnostic models for CAD and
thus better determine the appropriate model to apply to their
specific patient population. Clinicians should consider using
one of the higher-performing models that include readily
available risk factors. Accurate, simple diagnostic models are
more easily accepted in clinical decision making processes and
patient counseling. Additionally, this review could provide a
reference for future modeling efforts. The differing definitions
of CAD may affect the generalizability and calibration of the
models, and thus further model development and validation
studies with large cohorts and a wide variety of populations
are needed. We should acknowledge that the present review
has several limitations. First, the degree of stenosis in some of
the studies was determined by quantitative coronary angio-
graphy, whereas other studies used visual assessment. Second,
the studies included here involved heterogeneous populations
and had differing definitions for CAD, which could have led
to differential risks for CAD.
The available data indicate that current models for the PTP
calculation of CAD are still not fully refined. Although we
identified some higher-performing models, it is difficult to
generalize these to populations beyond those included in the
studies. Further research should focus on developing models
for predicting CAD that are better suited to broader popu-
lations. Adequate clinical trials need to be conducted to
assess the benefits of using these models in clinical practice
for cases where CAD is not suspected.
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